KRAS and colorectal carcinoma: Also, as EPCR mediates ERK phosphorylation in CRC cells, we hypothesised it could act as a bypass pathway during EGFR inhibition with cetuximab, similar to KRAS mutation 23, and might represent an additional negative predictive biomarker of cetuximab response.